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Nonalcoholic fatty liver disease (NAFLD) is a com-
mon, but often subtle, chronic liver disease that
ranges from steatosis alone to steatosis with in-
flammation, necrosis, fibrosis or cirrhosis.1 Recent
data indicate that NAFLD represents not only the
most common form of all liver disorders, but also
the most frequent cause of chronic liver disease.2
yNAFLD is characterized by asymptomatic, mildl
elevated serum aminotransferase levels in the
rabsence of significant alcohol intake or othe
chronic liver diseases.2 Primary NAFLD is caused
by conditions associated with insulin resistance
syndrome such as type 2 diabetes, obesity and
hyperlipidemia.2–5 A more severe type of NAFLD,
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Background/Purpose: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease rang-
ing in severity from steatosis to cirrhosis. Type 2 diabetes mellitus is a cause of primary NAFLD.
Thiazolidinediones have been shown to enhance insulin sensitivity, improve glycemic control in type 2
diabetes patients and to improve the histologic markers of nonalcoholic steatohepatitis. This study aims
to determine the safety and effectiveness of rosiglitazone in inadequately controlled type 2 diabetes pa-
tients with NAFLD.
Methods:  Taiwanese type 2 diabetes patients with inadequate control on insulin secretagogues and
metformin, with no history of significant alcohol ingestion, with mildly elevated serum aspartate amino-
ytransferase (AST) and/or alanine aminotransferase (ALT) and a diagnosis of fatty liver determined b
ultrasonography were enrolled. Patients were treated for 24 weeks with rosiglitazone, 4–8 mg daily.
Primary endpoints were change in AST and ALT levels from baseline and reduction in A1C < 6.5%.
Results: Out of a total of 68 patients, 60 (88.2%) completed the study treatment without serious adverse
events. Treatment in two (2.9%) patients was discontinued due to elevated AST or ALT levels to more than
three times the upper limit of normal, and noncompliance or loss of follow-up in six (8.8%) patients. Of the
60 patients who completed the study treatment, mean fasting plasma glucose, A1C, fasting plasma insulin,
mean ALT and homeostasis model assessment for insulin resistance were all significantly reduced. Normal
AST and ALT levels were achieved and maintained for at least three consecutive measurements and through
to the end of the study period in 20 (33.3%) patients. Weight increased by a mean of 2.6 ± 2.4 kg (p < 0.001).
Conclusion: Rosiglitazone was reasonably well tolerated in patients with inadequately controlled type 2
diabetes and NAFLD. One-third of patients showed improved liver function after treatment. [J Formos Med
Assoc 2006;105(9):743–752]
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nonalcoholic steatohepatitis (NASH), can lead to
progressive fibrosis and eventually cirrhosis.1 As
there is no therapy that has been demonstrated to
be effective for NAFLD, the focus of management
is to modify potential risk factors such as obesity,
hyperlipidemia and poor diabetic control.2,6
The thiazolidinediones (TZDs) have been
shown to enhance insulin sensitivity in periph-
eral organs and in the liver, thereby resulting in
improved glycemic control in patients with type
2 diabetes.7–13 Additionally, treatment of NASH
with rosiglitazone has improved insulin sensi-
tivity and the histologic markers of NASH.14
Rosiglitazone may also directly favourably influ-
ence necroinflammatory changes and fibrogenesis,
resulting in downregulation of the inflammatory
cascade and fibrosis.14 These benefits, therefore,
raise the potential of successfully treating type 2
diabetes patients who have NAFLD with TZDs.
Troglitazone, the first TZD, was found to im-
prove hepatic histology in patients with NASH,15
but the side effect of hepatotoxicity led to its sub-
sequent withdrawal from the market. The two
newer TZDs, rosiglitazone and pioglitazone, have
not demonstrated the high incidence of hepato-
toxicity seen with troglitazone.16 With accumulat-
ing exposure to rosiglitazone and pioglitazone in
clinical trials and in postmarketing experience,
there continues to be little evidence of drug-
induced hepatotoxicity.17,18 These newer TZDs
have also been reported to improve the biochem-
ical and histologic features of NASH and support
the role of insulin resistance in the pathogenesis
of this disease.14,19 However, since the subjects in
these studies were mostly nondiabetic patients
and since the study populations were small, the
efficacy and safety of TZDs in poorly controlled
diabetes patients with NAFLD remain unclear.
To our knowledge, the safety of rosiglitazone
and its effects on glucose and liver function in
poorly controlled type 2 diabetes with NAFLD
have not been previously evaluated. The primary
aim of this study was to determine the safety 
of rosiglitazone use in inadequately controlled
type 2 diabetes patients who have NAFLD and
who were already being treated with a tolerable
maximal dose of insulin secretagogues and met-
formin. The secondary aim of this study was to
cevaluate the glycemic and other nonglycemi
metabolic effects, including changes in liver func-
tion, in these patients.
Methods
Patient selection
This study was conducted at Mackay Memorial
Hospital in Taipei, Taiwan, between February 1,
2003 and June 30, 2004. Sixty-eight Taiwanese
patients with inadequately controlled type 2 dia-
betes who were on a tolerable maximum stable
regimen of insulin secretagogues (glibenclamide
20 mg/day, gliclazide 320 mg/day, glimepiride
6–8 mg/day or repaglinide ≥ 6 mg/day) and met-
formin (≥  1500 mg/day) for at least 3 months
before the study period were enrolled.
rOther inclusion criteria were age 18 years o
older; glycosylated hemoglobin (A1C) ≥ 7.0%; 
no history of alcohol intake or absence of signifi-
cant alcohol ingestion (< 70 g/week); mildly ele-
vated levels (up to 2.5 times the upper limit of the
normal range [ULN]) of serum aspartate amino-
transferase (AST) (36–88 U/L; reference range,
5–35 U/L) and/or of alanine aminotransferase
(ALT) (31–75 U/L; reference range, 5–30 U/L)
recorded at least three times within 1 year before
the study, with ALT levels higher than AST levels;
negative diagnostic tests for viral hepatitis B and
C, and a body mass index (BMI) < 40 kg/m2.
Fatty liver was determined by abdominal ultra-
sonography, which presented as diffusely increased
brightness and echogenicity.
Exclusion criteria included the following: cur-
rrent or previous treatment with rosiglitazone o
with other TZDs; pregnancy; lactation; clinical
evidence of active liver disease; normal or > 2.5
times the ULN levels of AST and/or of ALT; sec-
ondary causes of fatty liver, such as gastrointesti-
nal bypass surgery or medications that induce
csteatosis; more than one episode of hypoglycemi
unawareness; clinically significant heart failure
(NYHA Fc ≥ III) and peripheral edema.
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Throughout the course of this study, patients
were instructed to continue with the same lifestyle,
including diet and exercise, that they had main-
tained before study entry. Patients were allowed
to continue using antihypertensive and lipid-
lowering agents if they had been taking a stable
dose for at least 8 weeks before study entry.
During the entire study, the study protocol re-
quired that patients maintain their respective
doses of these agents at the same levels as before
study entry.
Study design
This prospective, open-labeled study consisted of
a 4-week screening period followed by a treatment
with rosiglitazone period that lasted at least 24
weeks. Enrolled patients underwent a comprehen-
sive medical history and physical examination.
All patients gave written informed consent for
study participation.
Laboratory measurements included A1C, fast-
ing plasma glucose (FPG), AST and ALT at 
baseline and after 4, 8, 12, 16 and 24 weeks of
treatment; and fasting plasma insulin, total cho-
lesterol (TC), triglycerides (TG), HDL-cholesterol
(HDL-C) and LDL-cholesterol (LDL-C) at base-
line and after 24 weeks of treatment. Dyslipi-
demia was defined as TC ≥ 200 mg/dL and/or
TG ≥ 200 mg/dL.
Postprandial glucose and insulin levels were
measured at baseline and after 24 weeks of treat-
ment. Body composition analysis was performed
at baseline and after 24 weeks of treatment. 
Body weight was measured to the nearest 0.1 kg
at baseline and at 4-week intervals. All patients
were started on a 4 mg daily dose of rosiglita-
zone and were titrated up to 8 mg/day at 4-week
intervals if their A1C levels remained ≥ 6.5%.
The study protocol required no dose adjust-
ments to be made of other oral hypoglycemic,
antihypertensive and/or lipid-lowering agents
during rosiglitazone treatment.
The response group was defined as patients
who achieved normal AST and ALT levels and,
on follow-up, continued to maintain normal
AST and ALT levels on at least three consecutive
yassessments and through to the end of the stud
period.
Safety parameters were assessed during each
clinic visit. During therapy, any patient who de-
veloped AST and/or ALT ≥ 3 × tULN, significan
weight gain that was unacceptable to the patient,
cserious adverse effects, including heart or hepati
failure, or any episode of severe hypoglycemia,
was withdrawn from the study. Severe hypo-
gglycemia was defined as hypoglycemia requirin
hospitalization or the assistance of another per-
son to treat and/or blood glucose < 50 mg/dL.
Follow-up abdominal sonography was performed
after 6 months of rosiglitazone use.
Measurements
Plasma glucose level was determined by the 
yhexokinase enzymatic method, insulin level b
the Coat-A-Count radioimmunoassay procedure
(Diagnostic Products Corporation, LA, USA)
and A1C by the high-performance boronate
affinity liquid chromatography method (Primus
CLC385TM System, MO, USA) with a normal range
yof 4.5–5.7%. AST and ALT were determined b
the tris buffer without pyridoxal-5-phosphate
method. The peroxidase method was used for TC
tdetermination, lipase method for TG, and direc
immunoinhibition method for HDL-C. LDL-C
was measured by the Triblock copolymer and
ca-cyclodextrin sulfate method and the enzymati
colorimetric method (both using the Hitachi 747
automatic analyzer, Tokyo, Japan). The home-
ostasis model assessment for insulin resistance
(HOMA-IR) was calculated from fasting plasma
insulin and FPG measurements, according to the
formula: HOMA-IR = fasting plasma insulin (μU/
mL) × fasting plasma glucose (mmol/L)/22.5.20
Blood pressure was measured before com-
mencement of and 6 months after starting rosigli-
tazone treatment. Waist circumference (WC) was
measured midway between the iliac crest and
ythe lowest rib at the end of expiration. Bod
composition was measured using an eight-
point tactile electrode, multifrequency segmental
bioelectric impedance analyzer (InBody 3.0,
fBiospace Co., Ltd, Seoul, Korea) after 8 hours o
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fasting, in accordance with the manufacturer’s
instructions. Measurements were taken at base-
line and after 24 weeks of treatment.
Statistical analysis
Descriptive statistics were used to summarize de-
mographic and biochemical characteristics at base-
line and after 24 weeks of rosiglitazone treatment.
Paired Student’s t test was used to compare changes
in parameters at baseline and after treatment. One-
way analysis of variance (ANOVA), χ2 and Fisher’s
exact tests were used to assess A1C change with
time and change in percentage of cases with nor-
malized AST and ALT with time. Stepwise regres-
sion analysis was performed using SPSS version 11
(SPSS Inc, Chicago, IL, USA) to evaluate the rela-
tionship between ALT and A1C, HOMA-IR, body
weight and fat mass. Simple linear correlation was
used to evaluate the relationship between change
in weight and A1C, weight and fat mass, A1C and
ALT, and HOMA-IR and ALT. A p value <0.05 was
considered statistically significant.
Results
Of the 68 patients, 60 (88.2%) completed the
study treatment while eight (11.8%) discontinued
treatment. Reasons for withdrawal and discontinu-
ation of treatment were as follows: elevated AST or
ALT levels ≥3×ULN in two patients (at 84 and 196
days, respectively), with peak AST and ALT values
of 106 and 98 for AST, and 65 and 52 for ALT, re-
spectively; noncompliance or loss of follow-up in
six patients (at 28, 49, 69, 127, 151 and 163 days,
respectively). Of the six patients with noncompli-
ance or loss of follow-up, four did not return to the
outpatient clinic for various periods of time during
the severe acute respiratory syndrome outbreak in
Taiwan. There was loss of follow-up in the other
two patients. These six patients were excluded from
the analyses. At the end of the study, the mean
dose of rosiglitazone in the remaining patients was
7.7 mg/day and 58 (92%) were taking 8 mg/day.
The clinical and biochemical characteristics
of the patients at baseline and after 24 weeks of
rosiglitazone treatment are shown in the Table.
yRosiglitazone treatment decreased mean FPG b
45 ± 45 mg/dL (p < 0.001), A1C by 1.4 ± 1.1% (p <
0.001), fasting plasma insulin by 4.2 ± 7.2 μ LU/m
(p < 0.001), 2-hour postprandial glucose by 51 ±
95 mg/dL (p < 0.001) and HOMA-IR by 2.88 ±
3.65 (p < 0.001).
Mean A1C reduced significantly from a base-
line of 8.4 ± 1.3% to <  7.0% in 60% (36/60)
and < 6.5% in 30% (18/60) of the patients.
Mean ALT decreased significantly from 47 ±
13 U/L to 35 ± 17 U/L (p < 0.001), and AST de-
creased from 32 ± 10 U/L to 30 ± 12 U/L, although
this change was not significant (p = 0.333). Mean
yTC, LDL-C and HDL-C all increased significantl
(9.2%, 15.9% and 6.0%, respectively, p < 0.005),
while TG decreased by 10.9%, although this re-
duction was not significant (p =  0.195). Mean
diastolic blood pressure showed significant re-
duction at the end of the treatment period from
80 ± 10 mmHg to 76 ± 9 mmHg (p = 0.003), while
mean systolic blood pressure showed no signifi-
cant change.
Weight increased in 88.3% (53/60) of pa-
t tients over the treatment period. Mean weigh
increased by 2.6 ± 2.4 kg (p < 0.001). Although
the incidence of mild to moderate clinical edema
 was 20.0% (12/60), it was not severe enough
yto require discontinuation of treatment in an
patient. There was a significant increase in mean
fat mass (2.0 ± 3.0 kg, p < f0.001), percentage o
body fat (1.7 ± 3.6%, p < 0.001) and BMI (1.1 ±
1.1 kg/m2, p < f0.001). However, the weight o
total body water did not change significantly.
Mean WC decreased by 2.0 cm (p < 0.05), while
mean waist/hip ratio (WHR) reduced by 0.06 ±
0.08 (p < 0.001).
The mean level of A1C with time and the per-
rcentage of patients with normalization of live
function in the response group with time are
shown in Figure 1. Mean A1C decreased rap-
idly during the first 8 weeks of treatment, from
8.4% to 7.4% (p < 0.001), with a slower but con-
ytinued decrease to 7.0% by the end of the stud
period. Before the addition of rosiglitazone,
63.3% (38/60) of patients had dyslipidemia,
C.H. Wang, et al
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while 70.0% (42/60) had dyslipidemia at the
end of the study (p = 0.44). In the response
group, normalization of liver function was first
noted as early as the 4th week after starting
rosiglitazone in 15% (9/60) of patients. This
incidence increased to 22% (13/60) by the 8th
week and to 33.3% (20/60) by the 12th week.
cThere was no significant difference in metaboli
Rosiglitazone in diabetic patients with NAFLD
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Table. Biochemical and clinical characteristics of the patients at baseline and after 24 weeks of rosiglitazone
treatment (n = 60)*
Baseline 24 wk Mean change p†
Age (yr) 56.9 ± 8.6
Sex (M/F) 27/33 
A1C (%) 8.4 ± 1.3 7.0 ± 1.0 − 1.4 ± 1.1 < 0.001
SBP (mmHg) 134 ± 13 133 ± 11 − 1.8 ± 13.8 0.308
DBP (mmHg) 80 ± 10 76 ± 9.0 − 3.8 ± 9.0 0.003
Fasting glucose (mg/dL) 187 ± 50 142 ± 35 − 45 ± 45 < 0.001
Fasting Insulin (μU/mL) 12.8 ± 7.0 8.6 ± 5.5 − 4.2 ± 7.2 < 0.001
HOMA-IR 5.88 ± 3.79 3.01 ± 1.96 − 2.88 ± 3.65 < 0.001
2-hr glucose (mg/dL) 330 ± 90 279 ± 66 − 51 ± 95 < 0.001
2-hr insulin (μU/mL) 32.9 ± 15.4 32.3 ± 22.0 − 0.6 ± 18.1 0.811
AST (U/L) 32 ± 10 30 ± 12 − 2.0 ± 13 0.333
ALT (U/L) 47 ± 13 35 ± 17 − 12 ± 16 < 0.001
Total cholesterol (mg/dL) 188 ± 25 205 ± 37 17 ± 31 < 0.001
HDL-C (mg/dL) 42.5 ± 8.0 45 ± 8.7 2.5 ± 6.6 0.005
LDL-C (mg/dL) 119 ± 27 138 ± 36 19 ± 28 < 0.001
Triglyceride (mg/dL) 231 ± 143 206 ± 141 − 25 ± 149 0.195
Body weight (kg) 71.3 ± 13.1 73.9 ± 13.8 2.6 ± 2.4 < 0.001
BMI (kg/m2) 27.8 ± 3.6 28.8 ± 4.0 1.1 ± 1.1 < 0.001
Body water weight (kg) 33.9 ± 7.0 34.2 ± 6.9 0.3 ± 2.0 0.306
Fat mass (kg) 22.3 ± 6.3 24.3 ± 7.5 2.0 ± 3.0 < 0.001
Body fat (%) 31.1 ± 5.9 32.8 ± 6.9 1.7 ± 3.6 < 0.001
Waist circumference (cm) 94.2 ± 9.7 92.2 ± 10.3 − 2.0 ± 7.1 0.036
WHR 0.97 ± 0.07 0.91 ± 0.07 − 0.06 ± 0.08 < 0.001
*Data are presented as mean± standard deviation; †paired Student’s t tests. A1C = glycosylated hemoglobin; SBP = systolic blood pres-
sure; DBP = diastolic blood pressure; HOMA-IR = homeostasis model assessment for insulin resistance; AST = aspartate aminotransferase;
ALT = alanine aminotransferase; HDL-C = HDL-cholesterol; LDL-C = LDL-cholesterol; BMI = body mass index; WHR = waist/hip ratio.
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parameters such as FPG, 2-hour postprandial
glucose, A1C, HOMA-IR, TC, TG, HDL-C, LDL-C,
ALT and AST at baseline between the response
and nonresponse groups.
Stepwise regression analysis showed no signifi-
cant correlation between ALT and A1C, ALT and
HOMA-IR, ALT and body weight as well as ALT
and fat mass. Linear regression analysis showed
significant correlations between change in weight
and A1C (p = 0.007), and change in weight and
fat mass (p = 0.001) (Figure 2). Follow-up abdom-
inal sonography after rosiglitazone treatment did
not show significant change in the fatty liver sta-
tus in either the response or nonresponse group.
Of the initial 68 patients, only two patients
(2.9%) withdrew due to elevated AST or ALT ≥ 3 ×
ULN. In one of the two patients who withdrew due
to elevated liver transaminase levels, follow-up
after discontinuation of rosiglitazone showed AST
and ALT levels had reduced to < 3 × ULN. In the
other patient, AST and ALT levels fluctuated after
stopping rosiglitazone but remained > 3 × ULN.
Both patients were otherwise stable. No patient
developed episodes of hypoglycemia, heart fail-
ure, weight gain or other side effects severe enough
tto necessitate withdrawal from the treatmen
protocol.
Discussion
Of the initial 68 patients, 88.2% completed the
tentire 24-week course of rosiglitazone treatmen
yand only two patients withdrew from the stud
due to elevated AST or ALT ≥ 3 × gULN. Excludin
the six patients with loss of follow-up or non-
compliance, 96.8% (60/62) of patients completed
the treatment course. There were no serious
adverse events, although mean body weight sig-
tnificantly increased. These results suggest tha
rosiglitazone is safe for use in inadequately con-
trolled type 2 diabetes patients with NAFLD and
mildly elevated liver enzymes.
In this study, the addition of rosiglitazone to
an established regimen of insulin secretagogues
gand metformin was effective in further lowerin
A1C and FPG in patients with inadequately con-
trolled type 2 diabetes. The addition of rosiglita-
zone resulted in a further reduction of mean A1C
by 1.4% (p < R0.001), with a decrease in HOMA-I
C.H. Wang, et al
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by 2.88 (49.0%, p < 0.001) (Table), which was
greater than the 18.6% to about 43% decrease re-
ported in previous studies.7,8,21 At the end of the
24-week treatment period, the response group
comprised 33.3% of patients. Normalization of
liver function was first noted in 15% of the pa-
tients as early as 1 month after starting treatment.
The pathogenesis of NAFLD has not been
clearly established. The prevailing theory is the
“two hits” hypothesis proposed by Day and James
in 1998.22 The first “hit” is attributed to the accu-
mulation of fat within the liver, while the second
“hit” is attributed to oxidative stress, which can
initiate fibrosis via proinflammatory cytokines.
Several studies have demonstrated that insulin re-
sistance is associated with NAFLD,3–5 and the
severity of insulin resistance tends to increase with
the stage of NAFLD.23
Improvement in liver function was found in
previous trials of pioglitazone treatment in pa-
tients with type 2 diabetes.24,25 In addition, the in-
cidence of elevated AST or ALT ≥ 3 × ULN was low
(0–2.4%) in previous trials of TZD monotherapy
or combined therapy,7,8,21,24–29 as in this study
(3.2%).
TZDs have been reported to improve the
biochemical and histologic features of NASH
in nondiabetic patients.14,15,19 In a prospective
pilot study, 18 nondiabetic patients with biopsy-
proven NASH were treated with pioglitazone for
48 weeks. By the end of the 48 weeks, serum ALT
had decreased to normal in 72% of patients.
Hepatic fat content and size as determined by
magnetic resonance imaging (MRI) were also de-
creased. Using strict criteria, histologic improve-
ment occurred in two-thirds of patients. There
was a strong positive correlation between changes
in fat in the liver, as determined by MRI, and de-
gree of steatosis, as determined by liver biopsy.19
In another study, adults with biopsy-proven NASH
were treated with rosiglitazone for 48 weeks.
The 25 patients who completed the treatment
had significantly improved insulin sensitivity
and mean serum ALT levels (104 IU/L initially,
42 IU/L at the end of treatment). The mean global
necroinflammatory score significantly improved
with treatment, and the biopsies of 10 patients
r(45%) no longer met the reported criteria fo
NASH after treatment.14 These results indicate
that treatment with TZD can lead to improve-
ment in the biochemical and histologic features
of NASH and support the role of insulin resist-
ance in the pathogenesis of this disease.14,19 rFo
patients with inadequately controlled type 2 dia-
rbetes and NAFLD with mildly abnormal live
function, the results of this study suggest that a
trial of rosiglitazone can improve liver function
within 3 months in one-third of patients. These
rpatients require long-term follow-up to monito
blood glucose control, liver function, NAFLD
change and insulin sensitivity.
The present study suggests that rosiglitazone
is safe and has beneficial effects on liver function
in poorly controlled type 2 diabetes patients with
NAFLD. Improved liver function may result from
several factors. First, TZDs improve insulin resist-
ance by increasing insulin sensitivity in peripheral
organs and in the liver.7–13 Second, TZDs improve
several components of the metabolic syndrome
that could beneficially affect endothelial function,
including reduction in circulating concentration
of free fatty acids and improvement of lipid pro-
file.7–9,12,13 Third, TZDs have important anti-
ginflammatory effects that involve decreasin
adipocytokine levels (e.g. TNF-α, PAI-1),10–13,30–32
ywhich are reflected by reduced high-sensitivit
C-reactive protein levels, increasing adiponectin
levels and attenuating monocyte chemoattrac-
tant protein-1.33 TZDs have been shown to de-
crease inflammatory markers much earlier than
a fall in either insulin or glucose concentrations
in diabetes.34 Our study confirmed this finding,
rwith a fairly rapid initial improvement in live
function observed much earlier than a fall in
tglucose concentration. Decrease in A1C was no
associated with a change in ALT, and no associa-
Rtion was found between change in HOMA-I
and ALT as shown in Figure 2. These findings sug-
gest that rosiglitazone may have effects beyond
glucose lowering, such as anti-inflammatory ef-
t fects, which are responsible for improvemen
of liver function. There was no significant change
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in fatty liver after rosiglitazone use, as determined
by abdominal sonography in either responders
or nonresponders. This could be due to the 
relatively short duration of treatment, with bio-
chemical changes preceding imaging alterations.
The lack of significant correlation between A1C
or HOMA-IR and ALT may have been due to the
small decrease in ALT and/or the relatively short
treatment period.
The mean body weight increase of 2.6 kg 
over the 24-week treatment period was mainly
attributed to increased mean fat mass (2.0 kg).
The incidence of peripheral edema was 20.0%,
which is higher than was reported with TZD
monotherapy or therapy with sulfonylureas and/
or metformin (4.1–12.4%).7,8,21,24–28 However,
both WC and WHR significantly decreased after
rosiglitazone use (Table), which indicates a more
peripheral redistribution of fat. Previous reports
also indicated that the weight gained during the
use of these drugs tends to be peripheral fat rather
than visceral fat and, therefore, may not be asso-
ciated with increased risks linked to the meta-
bolic syndrome.10–13
Similar to the findings in other studies, rosigli-
tazone treatment resulted in an increase in mean
TC, LDL-C and HDL-C.7,8,21 There was a decrease
in TG in this study, although the change was 
not significant. Mean diastolic blood pressure
decreased significantly after rosiglitazone use.
Insulin resistance and hyperinsulinemia have been
shown to be causally related to hypertension
through direct effects on vascular tone, stimula-
tion of the adrenergic nervous system and anti-
natriuresis.35 In this study, HOMA-IR improved
after rosiglitazone use and the reduction in dias-
tolic pressure could be due to the improved in-
sulin sensitivity. Diagnosis of NAFLD is based on
noninvasive and invasive tests, with liver biopsy
being the most definitive modality. The major
limitation of this study was the lack of confirma-
tive NAFLD by liver biopsy, although this confir-
mation would not be practical in most clinical
settings. In clinical practice, steatosis is commonly
detected by noninvasive imaging with ultrasonog-
raphy, computed axial tomography (CT) and MRI.
Among these imaging methods, sonography is
the least expensive and MRI is the most expensive.
When CT is used in the diagnosis of NAFLD, di-
agnostic accuracy is time-dependent and protocol-
specific, and there is considerable individual
yvariability as well as intraindividual variabilit
rduring multiple examinations in the absolute live
attenuation numbers.36 rArguments against live
fbiopsy include the generally good prognosis o
most patients with NAFLD, the lack of an estab-
lished effective therapy, and the risks and costs
associated with biopsy. In clinical practice, the
cdiagnosis of NAFLD is based on ultrasonographi
revidence of “bright liver” and reduced posterio
attenuation in subjects with no or moderate al-
cohol consumption.37 Selecting imaging studies
gover liver biopsy has the advantage of avoidin
the risks associated with an invasive procedure.
yUltrasonography defines increased echogenicit
in NAFLD and is thought to be a reasonably sen-
sitive study.38
The treatment duration of 24 weeks in this
study is relatively short. Further long-term studies,
ywhich combine the assessment of inflammator
markers with CT, MRI or liver biopsy, are needed
to determine whether improvements in liver func-
tion are due to improvement in fatty liver, and
to what extent they can be sustained over a
prolonged period.
In conclusion, this study found that rosiglita-
zone was reasonably well tolerated, reduced FPG,
postprandial glucose and A1C levels, and im-
proved insulin sensitivity in patients with inade-
quately ycontrolled type 2 diabetes complicated b
NAFLD and mildly elevated transaminase levels.
One-third of patients also showed improved
tliver function. The findings of this study sugges
that rosiglitazone treatment may be appropriate
in carefully selected patients with monthly mon-
itoring of liver function.
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